RIBOZYME AND OMICS

Announcement / News

News

Rznomics Receives Preliminary KOSDAQ Listing Approval

  • 작성자
    관리자
  • 날짜
    2025-09-22
기사원문
Rznomics wins Korea Exchange preliminary KOSDAQ listing approval
Rznomics Inc., a biotechnology company specializing in RNA-based gene therapeutics, officially announced on the 22nd Sep that it has received approval for its preliminary listing review from the Korea Exchange (KRX). With NH Investment & Securities and Samsung Securities serving as joint underwriters, the company is now initiating the full-scale listing process with the goal of completing its Initial Public Offering (IPO) by the end of the year.

Founded in 2017, Rznomics develops innovative treatments for cancer and intractable rare diseases using its proprietary RNA replacement enzyme-based RNA editing and correction platform.

Prior to this approval, Rznomics received "A" grades from two evaluation institutions designated by the KRX. Furthermore, the company was recognized as the first "National Strategic Technology Company" by the Ministry of Science and ICT (MSIT) and the Korea Institute of Science & Technology Evaluation and Planning (KISTEP) in May last year. In September, it was officially designated as a company possessing and managing National Strategic Technology.

Leveraging these credentials, Rznomics is set to list via the "Deep Tech Special Listing". It is poised to become the first company among those managed by the MSIT to complete an IPO under this specialized track. Notably, the approval process was expedited, taking only 40 business days—five days shorter than the standard 45-day review period.

Rznomics currently maintains a robust pipeline of core assets targeting intractable cancers, including hepatocellular carcinoma (HCC) and glioblastoma (GBM), as well as rare diseases such as Alzheimer’s, hereditary retinitis pigmentosa (RP), and rare neurological disorders. Its lead candidate, RZ-001, an oncology gene therapy, has significantly enhanced its commercialization potential by receiving both Fast Track Designation and Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA).

In a major strategic milestone last May, Rznomics signed a global platform-based licensing agreement with Eli Lilly and Company to develop RNA editing therapies, validating the global competitiveness and commercial viability of its platform technology.

As domestic and international pharmaceutical companies increasingly seek new modalities—such as ADCs, Targeted Protein Degraders (TPD), and Cell and Gene Therapies (CGT)—Rznomics is expected to achieve rapid growth through further partnerships with global biopharma leaders.

"Rznomics is developing innovative therapeutics that overcome existing limitations based on the world’s first Trans-splicing Ribozyme platform," said Dr. Seong-Wook Lee, CEO of Rznomics. "Through this KOSDAQ listing, we will open a new paradigm for next-generation RNA editing therapies on the global stage."
PREV
Rznomics’ Anti-cancer Gene Therapy, RZ-001, Selected for National New Drug Dev...
LIST
LIST
NEXT
Rznomics to Participate in ‘BIO-Europe 2025’ to Expand Global Collaborations